Sign In
Section Navigation
Common TitleBI-1182.51
Official Title An Open Label, Randomized, Parallel-group Pharmacokinetics Trial of Tipranavir / Ritonavir (TPV/RTV), Alone or in Combination With RTV-boosted Saquinavir (SQV), Amprenavir (APV), or Lopinavir (LPV), Plus an Optimized Background Regimen, in Multiple Antiretroviral (ARV) Experienced Patients
Phase Phase II
ClinicalTrials.gov NCT00056641
Treatments
Tipranavir
Tipranavir Aptivus

Tipranavir

Tradename:AptivusOther Names:TPVClass:Protease Inhibitors (PI)
Categories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryBoehringer Ingelheim
References
  • Walmsley SL, Katlama C, Lazzarin A, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr. 2008;47:429-40.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.